Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Phase III MAIA study of Darzalex + Revlimid + dexamethasone shows survival benefits in multiple myeloma – Janssen Biotech

Written by | 20 Jun 2021

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase III MAIA (NCT02252172) study showing the addition of Darzalex (daratumumab) to lenalidomide… read more.

Health Canada approves Darzalex + bortezomib + cyclophosphamide + dexamethasone to treat light chain amyloidosis – Janssen Biotech

Written by | 9 May 2021

Health Canada has approved daratumumab injection (Darzalex SC), a subcutaneous formulation of daratumumab (Darzalex), for use in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd; VCd) in the treatment… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.